Advaxis (ADXS) Announces Earnings Results, Beats Estimates By $0.06 EPS
Advaxis (NASDAQ:ADXS) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06, Yahoo Finance reports. The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million. Advaxis had a negative net margin of 940.64% and a negative return on equity of 131.78%.
Advaxis (NASDAQ ADXS) opened at $1.95 on Wednesday. Advaxis has a 12 month low of $1.75 and a 12 month high of $9.55.
ADXS has been the topic of a number of research reports. HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald set a $19.00 price target on shares of Advaxis and gave the company a “buy” rating in a research note on Thursday, December 28th. Finally, ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.